Endogenous nucleic acids and their receptors may be involved in the initiation of systemic autoimmune diseases including rheumatoid arthritis (RA). As the role of the DNA sensing Toll-like receptor (TLR) 9 in RA is unclear, we aimed to investigate its involvement in the pathogenesis of autoimmune arthritis using three different experimental models of RA. The data obtained revealed involvement of TLR9 in the T cell-dependent phase of inflammatory arthritis. In rats with pristane-induced arthritis (PIA), TLR9 inhibition before disease onset reduced arthritis significantly and almost completely abolished bone erosion. Accordingly, serum levels of IL-6, a-1-acid-glycoprotein and rheumatoid factor were reduced. Moreover, in TLR9 À/À mice, streptococcal cell wall (SCW)-induced arthritis was reduced in the T celldependent phase, whereas T cell-independent serum-transfer arthritis was not affected. Remarkably, while TLR7 expression did not change during in vitro osteoclastogenesis, TLR9 expression was higher in precursor cells than in mature osteoclasts and partial inhibition of osteoclastogenesis was achieved only by the TLR9
| INTRODUCTION
Rheumatoid arthritis (RA) is the most common and most severe inflammatory joint disease. Apart from cartilage degradation, the predominant clinical feature of RA is bone erosion leading to irreversible destruction of the joints. The onset of RA is characterized by hyperplasia of the synovial lining and infiltration of immune cells such as neutrophils, T cells, B cells, dendritic cells (DC) or macrophages in the synovia of the joint. 1 In the past years, research has been particularly focused on autoantibodies and to a lesser extent also on autoreactive T cells. In the course of these investigations, the important role of the innate immune system in eliciting the autoimmune responses involved in RA has become increasingly evident. A family of pattern recognition receptors, the Toll-like receptors (TLRs), is known to bridge the gap between innate and adaptive immunity. and 7, are highly expressed in the synovial tissue of RA patients. 7, 8 Intra-articular injection of streptococcal cell wall (SCW) lysates containing components of Streptococcus pyogenes that activate TLR2
results in acute T cell-independent joint inflammation 9 while repeated intra-articular exposure to SCW fragments results in TLR4 activation and the development of a chronic destructive arthritis depending on T cells. 10, 11 Furthermore, endogenous RNA released from necrotic cells in the synovial fluid of RA patients has been
shown to activate synovial fibroblasts through TLR3. 4 In addition, involvement of TLR3 and double-stranded (ds) RNA in pristaneinduced arthritis (PIA) has been suggested. 12 However, the involvement of TLRs activated by single-stranded (ss) nucleic acids in the inflammatory processes of RA is not fully understood. It was recently
shown that TLR7 expression is elevated in synovial fluid monocytes of RA patients and correlates with increased tumour necrosis factor (TNF)-a levels. 13 In addition, reduction of collagen induced arthritis (CIA) in TLR7 À/À mice points towards the involvement of the RNAbinding TLR7 in disease maintenance. 14 Other studies suggest a role for TLR9, which senses unmethylated ssCpG DNA. 15 It has been demonstrated that unmethylated CpG motifs from bacterial DNA can induce arthritis by activating macrophages and their cytokine production indicating a pathogenic role for bacterial DNA in septic arthritis. 16 Consequently, inhibition of TLR9 by a suppressive ODN in CpG-induced arthritis was shown to improve the clinical outcome. 17 In contrast, activation of TLR9 in mice with K/BxN serum transfer arthritis led to a disease reduction. 18 Furthermore, involvement of nucleic acid recognizing TLRs in the pathogenesis of autoimmune arthritis has been reported in PIA. In this model, arthritis could be transferred into na€ ıve recipients with T cells that had been reactivated in vitro by the nucleic acid binding protein hnRNP-A2/B1
or ligands (nucleic acids) of TLR3, TLR7 or TLR9. 19 Interestingly, disease transfer was inhibited by chloroquine or pre-treatment of cells with nucleases.
To dissect the role of TLR9 in the pathogenesis of RA, we induced arthritis in TLR9 À/À mice and blocked TLR9 activation in PIA by applying suppressive ODNs which have previously been
shown to block TLR9 on murine and human cells in vitro. 20, 21 The data obtained demonstrate involvement of TLR9 in the T cell-dependent phases of erosive arthritis, suggesting a pathogenic role of endogenous DNA and TLR9 in the initiation of arthritogenic autoimmune responses.
| MATERIALS AND METHODS

| Toll-like receptor antagonists and agonists
Antagonists for TLR7 (IRS 661), TLR9 (IRS 869), the TLR9 agonist (1018 ISS) and a control ODN were purchased from Eurofins Genomics (Eurofins Genomics, Ebersberg, Germany). The sequences were previously published. 20 
| Pristane-induced arthritis (PIA)
Arthritis was induced in DA.1F rats by subcutaneous (s.c.) injection of 100 lL pristane (Sigma-Aldrich) at the tail base. Antagonist (250 lg), control ODN (250 lg) or vehicle was injected s.c. 2 times weekly, and animals were treated twice before disease induction.
Inhibitors were diluted in saline to a final volume of 100 lL. Phosphate-buffered saline (PBS) served as vehicle control. Rats were evaluated for arthritis symptoms every other day starting at day 10 after disease induction using a semi-quantitative scoring system. 22 Changes in body weight served as an additional measure of disease severity. 
| Induction of chronic SCW arthritis
Cell wall fragments from Streptococcus pyogenes T12 were prepared as described. 23 Unilateral chronic arthritis was induced by 4 weekly intra-articular injections of 25 lg SCW in 6 lL PBS into the right knee joint at days 0, 7, 14 and 21. The left joint was injected with saline as control. 
| Quantification of joint swelling in SCW arthritis
| Isolation of cells for FACS analysis and cell culture
Splenocytes from rat or mouse spleens were isolated by passing them through a nylon mesh and cultured in DMEM (Gibco) supple- 
| Real-time quantitative polymerase chain reaction (RT-qPCR)
Total RNA from cells was isolated using the RNeasy mini kit (Qiagen, Hilden, Germany). RNA was reverse transcribed into cDNA using the Omniscript RT kit (Qiagen). RT-qPCR was performed using LightCycler technology (Roche, Germany) and the Fast Start SYBR Green I kit. The expression of the target molecule was normalized to GAPDH. The primer sets used (all from Sigma-Aldrich) are listed in Table S1 .
| RT-qPCR from tissue extracts
Rat organs (dLN and spleens) were mechanically homogenized in TRIfast (Peqlab), followed by isolation of total RNA according to the manufacturer's instructions. mRNA was reverse transcribed into cDNA using the Omniscript RT kit (Qiagen).
| Detection of cytokines
Serum samples were obtained from anaesthetized mice and rats by puncture of the heart. The acute phase marker a-1-acid-glycoprotein (AGP) and rat IL-6 were measured by ELISA obtained from Life Diagnostics (West Chester, PA, USA) and BD Pharmingen, respectively.
ELISAs for mouse IL-6, TNF-a and IL-10 were from Thermo Fisher Scientific.
| Detection of rheumatoid factor
Rheumatoid factor (RF) levels in rat sera were quantified by ELISA as published 24 with minor modifications. ELISA plates (NUNC, Roskilde, Denmark) were coated o/n at 4°C with 10 g/L rabbit IgG (Sigma). Isotype-specific mouse anti-rat IgM (Pharmingen, San Diego, CA, USA) or goat anti-rat IgG antibody (Vector, Burlingame, CA, USA) conjugated to biotin was used for detection, followed by incubation with StreptAvidin-conjugated HRP (R&D Systems). The relative concentrations of RF were determined using high-titre reference sera obtained from rats with PIA. To investigate the influence of TLR9 on the development of PIA, we injected the TLR9 inhibitor into DA.1F rats 2 days before inducing arthritis. The rats were then treated twice a week with the antagonist, using a non-specific ODN and saline as controls ( Figure 1A ).
| Statistical analysis
Development of PIA was assessed until the rats were sacrificed on day 25 post-pristane injection. Rats treated with the TLR9 antagonist developed milder clinical signs of arthritis and showed significantly reduced paw swelling on day 25 compared with the control groups ( Figure 1B) . Furthermore, loss of body weight was delayed and much less pronounced in the group of the TLR9 antagonized rats in comparison with the control groups, resulting in a significantly higher end point body weight in the treatment group ( Figure 1C ).
F I G U R E 1 Treatment with the TLR9
antagonist IRS 869 reduces severity of PIA. A, DA.1F rats were prophylactically treated with the TLR9 antagonist, the control ODN or vehicle (phosphatebuffered saline, PBS) according to the treatment scheme. B, Paw swelling was assessed throughout the experiment starting at day 10, and end-point paw swelling was calculated for all groups at day 25. C, Weight changes were measured and calculated relative to the starting weight (day 0); end-point weight change was calculated for all groups at day 25 after disease induction. Graphs show mean AE SEM with *P < .05 (n = 6 animals/group) Clinical observations were confirmed by histomorphometric quantification of paraffin-embedded sections from tarsal joints (Figure 2) . Analysis of invading inflammatory cells into the joint revealed a significant decrease in the inflammation area in TLR9 antagonized rats compared to the control group (Figure 2A,E) . In line with this, the number of bone resorbing osteoclasts was diminished in the TLR9 antagonist group (Figure 2B,E) . In addition, the osteophyte area was reduced in TLR9 antagonized rats as compared to the control groups ( Figure 2C ). Analysis of toluidine blue-stained cartilage sections revealed a significant reduction in cartilage degradation in joints of TLR9 antagonized animals ( Figure 2D ,E).
Reduction in arthritis was accompanied by reduced levels of IL-6
( Figure 3A ) and the inflammatory marker alpha-1-acid glycoprotein in sera of animals treated with the TLR9 antagonist ( Figure 3B ). The occurrence of IgM-RF in PIA has previously been shown to correlate with arthritis development. 24 In line with these observations, levels of IgM-RF, but not IgG-RF were significantly reduced in animals that had received the TLR9 antagonist ( Figure 3C ,D).
3.2 | Therapeutically administered TLR9 antagonist has no effect on the progression of PIA
Next we investigated whether the TLR9 inhibitor could affect arthritis when administered therapeutically after disease induction. At the onset of arthritis (day 14), the rats were treated twice a week with the antagonist or vehicle until they were sacrificed on day 60 (Figure 4A) . However, in contrast to prophylactic application, therapeutically administered TLR9 inhibitor did not influence the clinical severity of arthritis ( Figure 4B ). In accordance with the clinical observation, inflammation, bone erosion and number of osteoclasts in the tarsal joints were not influenced ( Figure 4C ).
| Expression of nucleic acid sensing TLRs in lymphoid organs
Pristane is known to quickly accumulate in draining LNs (dLN) following injection, 25 leading to an increased number of apoptotic cells in the dLNs within 1-3 days. 26 To further analyse the involvement of TLR9 in the development of PIA, we isolated mRNA from spleen and the inguinal (ie, draining) LNs. In addition to TLR9, expression of TLR3 (dsRNA binding) and TLR7 (ssRNA binding) was assessed by RT-qPCR. There were no differences of TLR3, 7 and 9 levels in dLNs of rats treated with the TLR9 antagonist, control ODN or vehicle.
However, TLR9 expression was significantly decreased in all three groups in comparison with the na€ ıve control animals ( Figure S2A-C) .
In contrast to LNs, no differences in TLR expression could be detected between spleens of arthritic and na€ ıve rats ( Figure S2D-F) .
| Lack of a functional TLR9 does not affect K/ BxN serum-transfer arthritis
To further dissect the involvement of TLR9 in T cell-dependent versus T cell-independent phases of inflammatory arthritis, we Figure 5A ). In accordance with the clinical observation, the inflamed area, bone erosions, number of osteoclasts and cartilage destruction of the tarsal joints were not influenced by the lack of TLR9 ( Figure 5B ). Thus, TLR9 did not seem to have an influence on incidence and severity of serum-transfer arthritis.
| TLR9 is involved in the T cell-dependent phase of chronic SCW arthritis
To confirm the differential roles of TLR9 in T cell-dependent and T cell-independent arthritic processes, we next investigated the involvement of TLR9 in the course of repeated SCW arthritis, which is characterized by a T cell-independent initial phase after the first intra-articular SCW injection, followed by a T cell-dependent chronic phase after the fourth SCW reactivation. 11 We induced SCW arthri- Figure 5C ).
| TLR9 is differentially expressed in the course of in vitro osteoclastogenesis
As the number of osteoclasts was substantially reduced in TLR9
antagonized rats, we became interested to analyze the impact of TLR9 on in vitro osteoclast formation using bone marrow cells from wild-type mice, which were cultivated in the presence or absence of TLR9 and TLR7 antagonists or agonists, or a control ODN.
When the cells were exposed to TLR9 and TLR7 antagonists or agonists, the formation of osteoclasts was reduced by approximately 40% by the TLR9 but not the TLR7 antagonist or the control ODN ( Figure 6A ). Furthermore, in accordance with previously published observations, 28,29 both agonists completely blocked osteoclast formation ( Figure 6A ). As the TLR9 agonist CpG has been shown to exert different effects during in vitro osteoclastogenesis depending on the time-point of the exposure to CpG, leading either to enhanced or reduced osteoclast formation, 29 we sought to explore whether agonists and antagonists of TLR9 and TLR7 would still exert a suppressive effect when cells had been pre-incubated with RANKL.
Indeed, when cells were stimulated with RANKL 3 days prior to addition of the agonists or antagonists, the inhibitory effect
observed for the TLR9 agonist as well as the TLR9 antagonist was completely abolished as was the inhibitory effect of the TLR7 agonist ( Figure 6B ).
In addition, we analyzed the expression of TLR9 and TLR7 by RT-qPCR at different time points during in vitro osteoclastogenesis.
In osteoclast precursor cells, TLR9 expression was high on day 3 but decreased to almost background levels after 5 days ( Figure 6C ).
TLR9 expression was not influenced by antagonists but on day 5
appeared to be slightly, although not significantly, increased by the agonists, particularly by the TLR7 agonist (R-848). Expression of TLR7 did not change between day 3 and day 5, but increased bỹ 2-fold upon culture with the TLR7 or the TLR9 agonist, but this increase did not reach statistical significance ( Figure 6D ). Altogether, these data suggest a dynamic regulation of TLR9 expression and a phase-dependent role for this receptor during osteoclastogenesis.
| DISCUSSION
It is now widely accepted that RA is initiated by autoreactive T cells leading to the production of pathogenic autoantibodies such as RF or antibodies to citrullinated proteins (ACPA). However, the trigger- after the onset of arthritis, no protective effects were observed, F I G U R E 3 Serum levels of IL-6, AGP and RF are reduced in rats treated with the TLR9 antagonist. The TLR9 antagonist or vehicle (phosphate-buffered saline, PBS) was prophylactically administered to DA.1F rats as described. Serum samples were obtained from anaesthetized rats by puncture of the heart on the day of termination of the experiment. Levels of A, IL-6, B, alpha-1-acid glycoprotein (AGP), C, RF-IgM and D, RF-IgG were determined by ELISA. Graphs show mean AE SEM with *P < .05 and ***P < .005 (n = 6 for A; n = 8-9 for B, C and D with data pooled from two individual experiments) F I G U R E 2 Antagonizing TLR9 leads to reduced inflammation, cartilage degradation and osteoclast numbers in arthritic paws of rats with PIA. Formalin-fixed paws were stained with H&E, toluidine blue and for TRAP. A, Inflammation, B, number of osteoclasts, C, osteophyte area and D, cartilage loss was analyzed. Quantification was performed as described. Animals treated with the TLR9 antagonist show a reduction in all analyzed parameters compared to animals treated with vehicle or control ODN. E, A representative picture is shown for each treatment group and a na€ ıve animal, where white arrows indicate osteoclasts and black arrows are indicative of osteophyte areas. Graphs represent mean AE SEM with *P < .05 and **P < .01 (n = 5-6 animals/group) F I G U R E 4 Therapeutic treatment with the TLR9 antagonist does not lead to improvement of PIA. A, Animals were therapeutically treated with the TLR9 antagonist, starting at disease onset (day 14). B, Paw swelling and weight changes were measured throughout the course of PIA. In addition, formalin-fixed paws were analyzed and C, inflammation, erosion and number of osteoclasts was determined.
Results are shown as mean AE SEM with n = 5-8 animals/group F I G U R E 5 Lack of TLR9 leads to a reduced T cell-dependent phase of chronic SCW-arthritis. A and B, K/BxN serum-transfer arthritis was induced in TLR9 À/À and control wild-type mice. A, Clinical observation of wild-type (WT, TLR9 +/+ ; n = 5) or TLR9 knock-out (KO, TLR9
À/À ; n = 6) C57BL/6 mice with K/BxN serum-transfer arthritis and B, histological quantification of the tarsal joints of these mice revealed no differences in inflammation, bone erosion, number of osteoclasts (ie, TRAP-positive cells) or cartilage loss in TLR9 À/À animals as compared to wild-type mice. C, SCW arthritis was induced in TLR9 À/À (n = 6) and control wild-type (n = 6) mice by repeated intra-articular injections of 25 lg SCW into the right knee joint at days 0, 7, 14 and 21, and injection of saline as internal control into the left joint. Joint swelling was determined by measuring 99m Tc uptake by the right (inflamed) joint compared to the left (control) joint at several time points including the acute (d1 and d2), reactivation (d8, d15 and d22) and the chronic (d23 and d28) phase of arthritis. Right/Left ratio of the radioactive 99m Tc signal is depicted on the Y-axis. Results are presented as mean AE SEM with *P < .05 by Mann-Whitney U test versus WT mice indicating that PIA becomes independent of TLR9 signaling and T cells once the disease process has been set in motion.
In line with these observations, SCW-induced arthritis in TLR9 À/À mice was reduced only in the T cell-dependent phase. In contrast to PIA, the acute phase of SCW-induced arthritis is TLR2 dependent but shifts towards a TLR4 dependency in the chronic phase, in which TLR2 is no longer relevant. This phase is driven by T cells and completely abrogated in RAG2-deficient mice. 10, 11, 30 In fact, chronic SCW arthritis is also accompanied by bone destruction and enhanced expression of RANK, RANKL and cathepsin K protein in cortical bone, features that are also characteristic of RA. We have previously observed that in the chronic SCW-induced arthritis model, the expression of TLR9 mRNA is up-regulated after each SCW injection and the kinetics of TLR9 expression follows the arthritis reactivation pattern, suggesting a potential relevance for TLR9 also in this model. 33 The data obtained in TLR9 À/À mice now clearly demonstrate that TLR9 is indeed involved in this T cell-dependent phase of chronic SCW-arthritis, highlighting the relevance of TLR9 in T cell-mediated arthritic processes, and thus suggesting a potential role for endogenous TLR9
ligands also in SCW-induced arthritis.
In contrast to SCW-arthritis, TLR9 deficiency had no influence on K/BxN serum-transfer arthritis. This model does not involve T cells but rather reflects the effector phase of autoimmune arthritis 27 and allows for studying the impact of TLR9 on innate immune cells. [34] [35] [36] This observation is therefore in full agreement with the ineffectiveness of TLR9 inhibitory treatment when started after the onset of PIA.
The most remarkable histological finding of prophylactic TLR9 inhibition in PIA was the almost complete absence of osteoclasts and bone erosion. It is known that TLR9 stimulation influences the outcome of osteoclastogenesis in a time-dependent manner, leading to a profound reduction in osteoclastogenesis. 29 To further investigate this process, we performed osteoclast assays with bone marrow cells that had or had not been incubated with RANKL before adding TLR antagonists or agonists. Indeed, partial inhibition of osteoclastogenesis was achieved with the TLR9 antagonist, whereas the TLR7 antagonist was ineffective. However, this effect was only observed in unprimed, that is RANKL naive cells. It is conceivable that blocking of MAPK and NF-jB signaling by the TLR9 antagonist led to partial suppression of osteoclast formation, because both pathways are involved in RANKL-induced osteoclast differentiation.
Of note, the previously described suppression of osteoclastogenesis by TLR9 activation was shown to be caused by dephosphorylation of ERK. 
CONFLI CT OF INTEREST STATEMENT
The authors confirm that there are no conflicts of interest.
O R C I D
G€ unter Steiner http://orcid.org/0000-0002-5089-7405
